

Monthy 1st and 3rd Wednesday and 12:00pm-1:00pm EST 11:00am-12:00pm CST 09:00am-10:00am PST 4th Wednesday 12:00pm-1:00pm CST 01:00pmpm-2:00pm EST 10:00am-11:00am PST

South East Viral Hepatitis Interactive Case Conference



HEPATITIS C

EDUCATION . TRAINING . CONSULTATIVE SUPPORT . CO-MANAGEMENT

- HCV/HIV/HBV Telehealth- 3 Wednesdays a month
- HIV PrEP Telehealth 2nd Wednesday at noon





Volume 25, Number 1

Estimated HIV Incidence and Prevalence in the United States 2014–2018

- US population 330 million
- HIV -estimated 1.2 million aged 13 and older
- Thus HIV prevalence >1/330 Americans
 - Males- 0.7% (1/150 male Americans)
 - Females-0.2%



United States Preventive Services Task Force recommendations

GRADE A for HIV

Recommendation Summary

Population	Recommendation	Grade
Pregnant persons	The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.	A
Adolescents and adults aged 15 to 65 years	The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. See the Clinical Considerations section for more information about assessment of risk, screening intervals, and rescreening in pregnancy. GRADE B for BREAST CANCER SCREEING	A

Recommendation Summary

Population	Recommendation	Grade
Women aged 50 to 74 years	The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.	B
Women aged 40 to 49 years	The decision to start screening mammography in women prior to age 50 years should be an individual one. Women who place a higher value on the potential benefit than the potential harms may choose to begin biennial screening between the ages of 40 and 49 years.	C

Recommendations for Initiating ART for an HIV infected person

- ART (Antiretroviral therapy or HIV medications) is recommended for all HIV-infected individuals to reduce the risk of disease progression.
- Effective ART reduces transmission to almost "0"
- HIV is easier to treat than Diabetes, COPD, CHF
- Undetectable= Untransmissible





DHHS Guidelines: Recommended Regimens for **First-line HIV Antiretroviral Therapy**

Regimen

- INSTI BIC/TAF/FTC (Biktarvy[®])
 - DTG/ABC/3TC (Triumeq[®])
 - DTG + (TAF or TDF)/FTC (Tivicay® + Descovy® or Truvada®)
 - RAL + (TAF or TDF)/FTC (Isentress[®]+Descovy[®] or Truvada[®])

IAS-USA now lists EVG/COBI/TAF/FTC and RAL + TAF/FTC as alternative regimens owing to their lower resistance barriers and, respectively, more drug interactions and higher pill burden



Class

DHHS Guidelines. 2019.

Dolutegravir controversy in pregnancy

Tsepamo Birth Outcomes Surveillance Study(Botswana)


• May 2018:

- Unplanned analysis of Tsepamo birth outcomes surveillance study found increase in NTD incidence among women who conceived on DTG^[1]
- DTG vs non-DTG ART: 0.94% (95% CI: 0.37-2.4) vs 0.12% (95% CI: 0.07-0.21)
- April 2019:
 - NTD prevalence among women who received DTG at conception lower than previous analysis, but still higher than other exposure groups^[2]
 - DTG vs non-DTG ART: 0.30% (95% CI: 0.13-0.69) vs 0.10% (95% CI: 0.06-0.17)
- April 2020:
 - Updated NTD prevalence
 - DTG vs non-DTG ART: 0.19% vs 0.11%

1. Zash. NEJM. 2018; 379:979. 2. Zash. IAS 2019. Abstr MOAX0105LB. 3. Zash. AIDS 2020. Abstr OAXLB01.



Life Expectancy in Patients With HIV Is Increasing: The "Graying" of the HIV Epidemic



Marcus JL, et al. J Acquir Immune Defic Syndr. 2016;73:39-46.

Slide credit: clinicaloptions.com

Hepatitis C Screening Recommendations

Population	Recommendation	Grade (What's This?)
Adults aged 18 to 79 years	The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years.	В

One-Time Hepatitis C Testing

	RECOMMENDED	RATING 0
One-time, routine, opt out H and older.	CV testing is recommended for all individuals aged 18 ye	ears I, B
	d be performed for all persons less than 18 years old with nditions or circumstances associated with an increased ri	
	should be offered to all persons with behaviors, exposur associated with an increased risk of HCV exposure (see	



Hepatitis C

- The most important risk factor for HCV infection is past or current injection drug use
 - The estimated prevalence of chronic HCV infection is approximately 1.0% (2013 to 2016) *Hofmeister MG, Hepatology. 2019;69(3):1020-1031*
- In the US, an estimated 4.1 million persons have past or current HCV infection
 - Positive for the anti-HCV antibody
- Approximately 2.4 million have current infections
 - Based on testing with molecular assays for HCV RNA. Chou R, Dana Agency for Healthcare Research and Quality; 2020. AHRQ publication




Genotypes

HCV- 6 major genotypes

- GT 1 -60-75% (most common in US, Europe, Latin America)
- GT 2- 13%
- GT 3-12%;
 - GT 4 -1%
 - GT 5 and GT 6 < 1%</p>
- Germer JJ,et al: J Clin Microbiol. 2011;49(8):3040–3043.
- GT3
 - Common in India, Far East, Australia
 - Increase in worldwide prevalence of GT 3 in IVDUs
 - Kanwal F, et al. Hepatology. 2014;60(1):98–105.
- There are 67 subtypes
 - GT1 that cannot be subtyped should be treated as genotype 1a infection.



Natural History of HCV Infection



FULL TEXT ARTICLE

Prevalence of Spontaneous Clearance of Hepatitis C Virus Infection Doubled From 1998 to 2017 A

- Spontaneous clearance occurs in approximately 25%-45% of acute infections
 - Higher spontaneous clearance in younger patients
- Detectable HCV RNA -within 1–2 weeks of exposure
- Anti-HCV Antibody- 8–11 weeks after exposure





Fibrosis Assessment:

- Transient elastography
 - > 12.5 KPa = cirrhosis
- Serum tests
 - FibroTest (0.75 = cirrhosis)
 - APRI or FIB-4 very attractive, can be done anywhere by any provider
 - Very good negative predictive value rule out cirrhosis
- Ultrasound not needed in all patients
 - Insensitive for cirrhosis only needed if cirrhotic to exclude HCC before treatment
- Biopsy rarely needed

HIV/HCV Co-infection

- All persons living with HIV should be screened for HCV
 - Those at high risk of HCV should be screened annually
 - MSM, PWID
- HIV is independently associated with the progression of HCV (liver fibrosis and cirrhosis)
 - ART may slow the progression of liver disease
 - All HIV/HCV co-infected patients should be treated with HIV ART
- Similar effectiveness of HCV DAAs in HIV/HCV co-infection



Liver Fibrosis progression - HIV/HCV coinfection

- Observational cohort from Baltimore, Maryland
 - 1176 current and former IVDU.
- Factors associated with progression of liver fibrosis
 - High HIV Viral Loads
 - Low nadir CD4 counts
 - Alcohol use

Kirk GD, Ann Intern Med. 2013;158:658–666.

- Meta-analysis of 8 studies
 - More rapid progression of liver fibrosis in HIV/HCV co-infected
 - Adjusted relative risk (RR) 2.92 (progression to cirrhosis)

Graham CS, et al. Clin Infect Dis. 2001






Figure 1 - Progression to Cirrhosis in Patients with HCV Monoinfection and HIV-HCV Coinfection

Benefits of treating HIV/HCV coinfected patients

- HIV Antiretroviral therapy:
 - Slows the rate of HCV disease progression

Thein HH, et al. a meta-analysis; Hepatology 2008

- HCV DAA treatment : regression of liver stiffness post SVR
 - 129 patients HCV/HIV coinfected /85 patients monoinfected
 - ≥30% regression of liver stiffness in almost 50%
 - In mono-infected and co-infected groups

Malin JJ, et al. Liver stiffness regression after successful hepatitis C treatment :HIV Med. 2019

HCV treatment in HIV-infected patients - should be a priority for providers, payers, and patients.



Treatment of Chronic HCV

- Goal of Treatment is Sustained Virological Response(SVR)
 - SVR-undetectable HCV viral Load ≥12 weeks after treatment completion
- Current DAAs have SVR > 98% in
- Treatment is recommended for ALL pts with chronic hepatitis C infection
 - Exception: life expectancy likely to be < 6 months despite treatment or transplantation



Pan-genotypic Regimens

Sofosbuvir/Velpatasvir (Epclusa[®])

Glecaprevir/Pibrentasvir (Mavyret[™])

Reserved for treatment experienced

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)



HCV Direct Acting Antivirals

	GT 1	GT 2	GT 3	GT 4	GT 5	GT 6
GZR/EBR (Zepatier®)	~			✓		
*GLE/PIB (Mavyret®)	✓	✓	✓	✓	~	✓
SOF/LDV (Harvoni®)	~			~	~	~
*SOF/VEL (Epclusa®)	~	~	~	~	~	~
*SOF/VEL/VOX (Vosevi®)	~	~	~	~	✓	✓

*Pan-genotypic



Treatment options for GT1

4 highly potent DAA combination regimens available Baseline genotypic drug resistance testing is not recommended for most of the first-line DAA regimens Except elbasvir-grazoprevir.






Sofosbuvir/Velpatasvir (Approved July 2016)

- EPCLUSA :Fixed-dose combination of
 - Sofosbuvir (400 mg)- NS5B polymerase inhibitor
 - Velpatasvir (100 mg) HCV NS5A inhibitor
- Indicated for the treatment of adult patients with
 - Chronic HCV genotypes 1, 2, 3, 4, 5, or 6
 - Baseline resistance testing required only for GT 3
- •One tablet once daily with or without food



Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5:

ASTRAL-5: SVR12 Results by Genotype



Source: Wyles D, et al. EASL 2016, Abstract PS104.

Glecaprevir/ Pibrentasvir (Mavyret)

- Pangenotypic
- Coformulated into single tablet
 - Glecaprevir 300mg/ Pibrentasvir 120mg= target dose
 - Formulated as Glecaprevir 100mg/Pibrentasvir 40mg
 - 3 pills a day, with food
- Approved August 2017

are assand to more
New York (c) Conference on the formation of the second of
Take of a testing one stand
Pruch down on values breaking through last outs
work date the man

Glecaprevir/pibrentasvir HIV/Hepatitis C coinfection

- **EXPEDITION-2** study- HIV/HCV coinfection
- 8 weeks of GLE/PBV -137 adults without cirrhosis
- 12 weeks of GLE/PIB 16 with compensated cirrhosis.
 - Either antiretroviral naive with a CD4 ≥500/mm³
 - Or on ART regimen for 8 weeks with a CD4 \geq 200/mm³.
 - ART drugs included (raltegravir, dolutegravir, rilpivirine)- tenofovir disoproxil fumarate, tenofovir alafenamide, abacavir, emtricitabine, and lamivudine.
- Overall SVR12 was 98%




ORIGINAL ARTICLE



Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

Susanna Naggie, M.D., M.H.S., Curtis Cooper, M.D., Michael Saag, M.D., Kimberly Workowski, M.D., Peter Ruane, M.D., William J. Towner, M.D., Kristen Marks, M.D., Anne Luetkemeyer, M.D., Rachel P. Baden, M.D., Paul E. Sax, M.D., Edward Gane, M.D., Jorge Santana-Bagur, M.D., et al., for the ION-4 Investigators*

- 12 weeks of LDV/SOF
- GT1 or 4 HCV, 20% with compensated cirrhosis, 55% treatment experienced



Treating HIV/HCV GT1 Co infection

- Ledipasvir/Sofosbuvir (Harvoni[®])
 - Ledipasvir increases tenofovir levels when given as TDF
 - Avoid in patients with an eGFR <60 mL/min.
- Sofosbuvir/Velpatasvir (Epclusa[®])
- Elbasvir/Grazoprevir (Zepatier[®])
 - NS5A resistance testing needed
- Glecaprevir/Pibrentasvir (Mavyret[®]) x 8 weeks if non cirrhotic
 - Compounds that inhibit P-gp, BCRP, or OATP1B1/3 may increase glecaprevir and pibrentasvir concentrations.
 - Like Cobicistat which is in Genvoya
 - Monitor LFTs at 4 weeks if on a cobicistat based regimen
 - Drugs that induce P-gp/CYP3A may decrease glecaprevir and pibrentasvir concentrations
 - Like Efavirenz and Etravirine
 - Mavyret not approved for 8 weeks for HIV/HCV coinfected patients with cirrhosis
 - Expedition 8 did not have any HIV/HCV co-infected patients





HCV Therapy Highly Effective in HIV/HCV-Coinfected

	Study	Population	HCV Regimens	SVR12, %
HARVONI	ION-4 ERADICATE	N = 335; GT1 (98%) or GT4 N=50	LDV/SOF 12 wks	96 100
ZEPATIER	C-EDGE CO- INFECTION	N = 218; GT1, 4, 6	EBR/GZR 12 wks	96
EPCLUSA	ASTRAL-5	N = 106;18 % cirrhosis GT1-4	SOF/VEL 12 wks	95
MAVYRET	EXPEDITION-2 All patients had CD4 > 200	N = 163; <mark>GT1-6</mark> 137- no cirrhosis 16 comp cirrhosis	GLE/PIB for 8 wks for without cirrhosis and 12 wks with cirrhosis	98

Selected ART and HCV DAA Drug Interactions

HCV Regimen	Do NOT Use With:
EBR/GZR (Zepatier [®])	COBI, EFV, ETV, NVP, or any HIV PI
GLE/PIB (Mavyret [®])	ATV, <u>RTV</u> , EFV, or ETV
SOF/VEL (Epclusa [®])	EFV, ETV, or NVP
SOF/VEL/VOX (Vosevi [®])	ATV/RTV, EFV, ETV, or NVP

Existing data with Bictegravir suggests co-administration is safe

AETC AIDS Education & "Patients With HIV/HCV Coinfection: HCV Guidance." Patients With HIV/HCV Coinfection | HCV Guidance, 24 May 2018. Southeast Ahmed, Aijaz, et al. "Drug-Drug Interactions in Hepatitis C Virus Treatment: Do They Really Matter?" AASLD, John Wiley & Sons, Ltd, 30 Nov. 2017, aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/cld.668.

Benefits of Sustained Virologic Response (SVR)

- In a review of 3,010 treatment-naive patients
- **40% to 73%** of participants who achieved SVR had improvement in liver fibrosis and necrosis.
 - Cirrhosis resolved in 49% of the cases
 - Portal hypertension, splenomegaly, and other clinical manifestations of advanced liver disease also improved
 Poynard T, et al. Gastroenterology. 2002;122(5):1303-1313.
- SVR is associated with
 - >70% reduction in the risk of HCC
 - 90% decrease in liver-related mortality & liver transplantation

Van der Meer AJ, et al. JAMA. 2012;308(24):2584-2593





AASLD: New Simplified HCV Treatment Approach

Eligible Patients:

Chronic hepatitis C without cirrhosis and no previous HCV therapy

- Assess cirrhosis (liver biopsy not required)
 - Treat as though cirrhotic if any of the following suggest cirrhosis
 - FIB-4 > 3.25, platelet count < 150,000/mm³, APRI > 2.0, FibroScan > 12.5 kPa
- Record medications and supplements, assess DDIs
- Conduct recommended baseline labs
- Provide patient education

Treatment Options:

GLE/PIB 3 pills/day for 8 wks (with food) or SOF/VEL 1 pill/day for 12 wks

AASLD Guidance. November 2019.

Simplified Treatment algorithm: Not applicable to HIV-HCV co-infected patients

- Treating HIV-HCV coinfected patients has as good SVR rates as treating HCV mono-infected patients
- But caution with Drug interactions

Exclusions to Simplified Treatment

- Prior hepatitis C treatment
- End-stage renal disease
- HIV or HBsAg positive
- Current pregnancy
- Known or suspected hepatocellular carcinoma
- Prior liver transplantation
- Decompensated cirrhosis

AASLD/IDSA HCV Guidelines. 2019.



On-Treatment Monitoring

- Monitor blood glucose
 - Diabetics have the potential for hypoglycemia.
- Monitor INR if on Warfarin
- No laboratory monitoring is required for other patients.
- Consider an in-person or telehealth/phone visit for patient support and adherence



Post-Treatment Assessment of Cure (SVR)

- \geq 12 weeks after finishing DAA Treatment
 - Quantitative HCV RNA
 - LFT
 - If Liver enzymes persistently elevated then assessment for other causes of liver disease is recommended



Follow-Up After Achieving Virologic Cure (SVR)

- For patients without Cirrhosis who achieve SVR
 - No liver-related follow-up is recommended
- For patients with ongoing risk IVDU, MSM engaging in unprotected sex
 - Risk Reduction Counseling
 - Annual testing for HCV RNA.
- Advise patients to avoid excess alcohol use.



CASE PRESENTATIONS





Baseline Demographics						
Age: 69	Race: African American	Gender: Female		Primary Insurance: Medicare		
PMH/Comorbidities/Substance Use: Depression/1ppd x 50-year smoking history						
Pertinent Clinic	cal Findings: N/A	A				
Weight (kg):	86.8	Serum Albumin:	4.3	ALT:	11	
Hgb:	11.9	Total bilirubin:	0.2	AST:	14	
PLT:	229	INR:	1.0	SCr/CrCl:	0.98/74mL/mi n	



Case 215 – Dr. Ada Stewart

HCV Evaluation						
Ultrasound: Pending	CT: Not done					MRI: Not done
Signs of Cirrhosis:	no					
Staging Modality:	Results:	Results: Interpretation: APRI:				0.15
Fibroscan/Transient Elastography:	Not done	 FIB-4:			1.27	
Fibrosure:	0.36	F1-F2			1	
Treatment Naïve?:	Yes	If no, previous treatment: HIV Antiboo		ibody:	Positive, 4 th gen test – reactive, VL <20	
HCV Genotype:	1b	HCV RNA: 723,000 HAV Total Ab:		otal Ab:	Positive	
HBV sAb: Not on therapy	Negative	HBV sAg:	Positive	HBV T	otal cAb:	Reactive
Requested Regimen:	Epclusa x 12 we	eeks		•		·



Case 215 – Dr. Ada Stewart

- Medication List:
 - Mirtazapine 30mg daily
 - Sertraline 50mg daily
 - Hydroxyzine daily
 - HCTZ 12.5 mg daily
 - Alprazolam 0.5mg
 - Omeprazole will hold (acknowledged by provider)

- Clinical considerations:
 - GT1b
 - Treatment naïve
 - Metavir- F1-F2
 - HBV Co-infection
 - HIV-1 Co-infection?
 - Positive HIV-1 Ab (4/27/20)
 - Reactive 4th-generation +
 - Indeterminant HIV-1 Ab (8/28/20 and 9/10/20)
 - HIV VL < 20



HBV Evaluation

- Ensure adequate HBV evaluation prior to initiating HCV therapy
- HBV viral load needed to then address treatment plan and laboratory evaluation

Marker	Interpretation	Acute Infection	Window Period	Chronic Infection	Remote Infection	Immunization	Inactive Chronic Carrier
HBcAb	Exposure	+	+	+	+	-	+
HBsAg	Infection	+	-	+	-	—	—
HBsAb	Immunity	-	-	-	+	+	—



Risk for HBV Reactivation

- All HIV patients starting HCV medications should be assessed for HBV co-infection
 - HBsAg, anti-HBs, and anti-HBc testing
 - If Anti-HBs negative \rightarrow administer anti-HBV vaccination
- Persons with HCV/HIV coinfection and active HBV infection (HBsAg positive) should receive ART that includes two agents with anti-HBV activity prior to initiating HCV therapy



AASLD/IDSA HCV Guidelines. 2018.


Goals of Therapy for HBV



lifelong therapy



Options for HBV Treatment Dual therapy in HIV/HBV Co-infection



EASL. J Hepatol. 2017;67:370. Terrault. Hepatology. 2018;67:1560.




- FOR A DETAILED DISCUSSION OF HIV and HBV Coinfection
- Please join the Telehealth program at 1EST/12 CST next Wednesday (10/14/20)



HIV testing


Ē





HIV Evaluation

- Patients who receive a positive 4th generation HIV1/2 and p24 Ag combination immunoassay with indeterminate Ab should receive the HIV-1 NAT (PCR)
- HIV-1 NAT tests for the presence of HIV-1 RNA and should be performed as soon as possible



2014 Laboratory testing for the diagnosis of HIV: updated recommendations. CDC



Indeterminate HIV test results

- The initial test is a combination Ag/Ab immunoassay
 - The Ag disappears very quickly once Ab develops as the Ag and Ab form immune complexes
- If the HIV antibody differentiation assay is negative or indeterminate- check HIV-1 NAT to look for acute seroconversion
 - A negative NAT and indeterminate antibody immunoassay indicates a false positive immunoassay
- However, HIV-2 is a remote possibility and the majority of cases are reported in persons born in Africa
 - It is theoretically possible that acute HIV -2 infection might produce a repeatedly reactive HIV immunoassay but negative antibody



HCV Guideline Recommendations

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Patients Genotype 1b Without Cirrhosis

RECOMMENDED	DURATION	RATING 🕄
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg)	12 weeks ^a	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b	8 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL	8 weeks ^c	I, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

^a An 8-week regimen can be considered in those with genotype 1b infection and mild fibrosis (see text for details).

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

^c For HIV/HCV coinfected patients, a treatment duration of 12 weeks is recommended.



Drug Interactions – (FYI at this time) Proton Pump Inhibitors

DAA	Resource	PPIs (Omeprazole)	H2RAs (Famotidine)		
GLE/PIB - Mavyret®	Liverpool	No recommendation per product labeling	No recommendation per product labeling; AUC of GLE decreased by up to 50%		
	Lexicomp	Class B	No interaction		
GZR/EBR -	Liverpool	No inte	praction		
Zepatier®	Lexicomp	No interaction			
SOF/LDV -	Liverpool	20mg simultaneously on empty	Administer at same time or 12 hours		
Harvoni®	Lexicomp	stomach	apart; max dose: 40 mg BID		
SOF/VEL – Epclusa®	Liverpool	If medically necessary, take SOF/VEL with food 4hr prior to omeprazole 20 mg	Administer at same time or 12 hours apart; max dose: 40 mg BID		
	Lexicomp	Do not coadminister			
SOF/VEL/VOX - Vosevi®	Liverpool	Max 20 mg	Administer at same time or 12 hours apart; max dose: 40 mg BID		
	Lexicomp	Do not coadminister	Max dose: 40 mg BID		



Recommendations

- GT1b, treatment naïve, without evidence of advanced fibrosis
- HBV co-infected
 - Needs HBV Viral Load, If high needs eAg, eAb and Rx
- HIV- likely false positive
 - Consider repeat HIV 1 NAT and try and obtain HIV-2 NAT
- HCV DAA options:
 - Mavyret[®] GLE/PIB x 8 weeks
 - Epclusa[®] SOF/VEL x 12 weeks
 - Zepatier[®] EBR/GZR 12 weeks
 - Harvoni[®] LED/SOF x 12 weeks



Case 216 – Dr. Deanna Cotter

Baseline Demographics						
Age: 68	Race: African American	Gender: Female		Primary Insurance: Medicare		
PMH/Comorbidities/Substance Use: Chronic Kidney Disease						
Pertinent Clini	cal Findings: No	ne				
Weight (kg):	109	Serum Albumin:	3.8	ALT:	27	
Hgb:	14.6	Total bilirubin:	0.6	AST:	27	
PLT:	209	INR:	1.1	SCr/CrCl:	1.15/80mL/mi n	



Case 216 – Dr. Deanna Cotter

HCV Evaluation						
Ultrasound: Not done	CT: Not done					MRI: Not done
Signs of Cirrhosis:	no	no				
Staging Modality:	Results:	Interpretation: APRI:			APRI:	0.32
Fibroscan/Transient Elastography:	Not done	 FIB-4			FIB-4:	1.69
Fibrosure:	0.34	F1-F2				
Treatment Naïve?:	Yes	If no, previo treatment:	ous	HIV Ant	tibody:	Negative
HCV Genotype:	1b	HCV RNA:	5,690,000	HAV Total Ab:		Negative
HBV sAb:	Negative	HBV sAg:	Negative	HBV Total cAb:		Non-reactive
Requested Regimen:	Epclusa x 12, I	Epclusa x 12, Harvoni x 8 weeks, Mavyret x 8 weeks				



Case 216 – Dr. Deanna Cotter


Medication List:

- Atenolol daily
- Fluticasone nasal spray
- HCTZ 25mg daily
- Loratadine 10mg daily prn
- Losartan 100mg daily
- Oxybutynin ER 5mg daily
- Ventolin HFA prn
- Vitamin D3 2000 units daily
- Voltaren gel

Clinical considerations:

- GT1b
- Treatment naïve
- Metavir- F1-F2
- Simplified treatment regimens
 - Shortened course options





Treatment Options:

GLE/PIB 3 pills/day for 8 wks (with food) or SOF/VEL 1 pill/day for 12 wks

Commonly used Liver staging modalities

APRI FIB-4

• APRI

- AST to PLT ratio index
 - <0.5-low likelihood of fibrosis
 - >1.5: High likelihood of cirrhosis
- FIB-4

Southeast

- Age, AST, ALT, PLTs.
- <1.45: Low likelihood of fibrosis
- >3.25: High likelihood of cirrhosis

Fibrosure


Patented Blood test

- Measures-
 - alpha-2 macroglobulin, haptoglobin, GGT, ALT, and apolipoprotein A1
 - Gives a fibrosis score and inflammation score
 - >0.75 consistent with cirrhosis

Fibroscan


- Ultrasound Transient elastography
 - Non invasive
 - Equally accurate in measuring degree of liver inflammation and fibrosis as biopsy
 - > 9.5 is considered Metavir F3
 - > 12.5 (>14 in some studies) is consistent with cirrhosis (F4)

Transient Elastography






Mechanical Shear Wave Induction





a medovations company

Shear Wave Movement





a medovations company

Treatment Plan

Requested Regimens:

Epclusa x 12, <u>Harvoni x 8 weeks</u>, Mavyret x 8 weeks

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Patients Genotype 1b Without Cirrhosis

•
90

^a An 8-week regimen can be considered in those with genotype 1b infection and mild fibrosis (see text for details).

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

^c For HIV/HCV coinfected patients, a treatment duration of 12 weeks is recommended.



Pretreatment Assessment: Shortened-course Harvoni®

 Shortened course Harvoni (Ledipasvir/Sofosbuvir) for African Americans without cirrhosis has been evaluated in real-world cohorts

<u>Marcus, 2018</u> : 436 African American patients	SVR12 rates were 95.6% for 8- week therapy and 95.8% for 12- week therapy
Tang, 2018: 503 African American veterans	Primarily genotype 1 patients; SVR12 rates were 93.7% for 8- week therapy and 91.4% for 12- week therapy

- 1. Marcus JL, Hurley LB, Chamberland S. Clin Gastroenterol Hepatol. 2018;16(6):927-935.
- 2. Tang L, Parker A, Flores Y, et al. J Viral Hepat. 2018;25(2):205-208.



Recommendations

- GT1b, treatment naïve, without evidence of advanced fibrosis & HBV/HIV negative
 - HAV/HBV Vaccination needed
- DAA options:
 - Zepatier[®] EBR/GZR x 8 or12 weeks
 - STREAGER trial (GT1b, with low fibrosis defined as a TE score <9.5 or a Fibrotest[®] score <0.59 [F0 to F2], found an SVR rate of 98% (87/89)) while using 8 weeks of therapy
 - Harvoni[®] LED/SOF x 8 weeks
 - Mavyret[®] GLE/PIB x 8 weeks
 - Epclusa[®] SOF/VEL x 12 weeks





Case 217 – Dr. Andre

Baseline Demographics							
Age: 35	Race: White	Gender: Female		Primary Insurance: Private			
PMH/Comorbid	PMH/Comorbidities/Substance Use: diabetes, depression, s/p C section Feb 2020						
Pertinent Clinic	al Findings: None						
Weight (kg):	143	Serum Albumin:	3.5	ALT:	189		
Hgb:	11.9	Total bilirubin:	0.6	AST:	187		
PLT:	309	INR:	1.0	SCr/CrCl:	0.82/216.4		



Case 217 – Dr. Andre

		HCV Eva	luation			
Ultrasound: Not done	CT: Not done	CT: Not done				
Signs of Cirrhosis:	None					
Staging Modality:	Results:	Interpretation:			APRI:	1.51
Fibroscan/Transient Elastography:	Not done				FIB-4:	1.54
Fibrosure:	0.48	F2, severe necroinflammatory activity (0.81)				
Treatment Naïve?:	Yes	If no, previous treatment: HIV Antik		body:	Negative	
HCV Genotype:	1a	HCV RNA:	V RNA: 2,024,274 HAV Total A		otal Ab:	Negative
HBV sAb:	Negative	HBV sAg: Negative HBV Total		otal cAb:	Non-reactive	
Requested Regimen:	Epclusa x 12 w	eeks				



Case 217 – Dr. Andre

Medication List:

- Aspirin 81 mg daily
- Sprintec daily
- Ferrous sulfate 325 mg daily
- Novolin 70/30 24 units BID
- Synthroid 100 mcg daily
- PNV daily

Clinical considerations:

- GT1a
- Treatment naïve
- Cirrhosis assessment
 - APRI 1.51
 - FibroSURE- F2
- Simplified vs.
 comprehensive approach
- Drug interactions
- Needs vaccination





	GT1a, tx	naïve
 Assess cirrhosis (liver biopsy not required) Treat as though cirrhotic if any of the following suggest cirrhosis FIB-4 > 3.25, platelet count < 150,000/mm³, APRI > 2.0, <i>FibroScan</i> > 12.5 kPa Record medications and supplements, assess DDIs Conduct recommended baseline labs 		
 Provide patient education 	APRI	1.51
	FIB-4	1.54
	Fibrosure	F2
Treatment Options: GLE/PIB 3 pills/day for 8 wks (with food) or SOF/VEL 1 pill/day for 1	L2 wks	

SIMPLIFIED vs. STANDARD

Cirrhosis Assessment

- FIB-4 >3.25 OR
- Previously documented: FibroScan, FibroSure, clinical evidence of cirrhosis, biopsy
- If cirrhosis: CTP score and genotype testing

Coinfection Assessment

- HIV antigen/antibody
- Hepatitis B surface antigen

Cirrhosis Assessment

- Serologic: FIB-4, APRI, FibroSURE
- Non-invasive: FibroScan
- Genotype testing

Coinfection Assessment

- HIV antigen/antibody
- HBV surface antigen, surface antibody, core antibody



Recommendations

Southeas

GENOTYPE 1A

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 1a Patients Without Cirrhosis

RECOMMENDED	DURATION	RATING 🖸
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs for elbasvir ^a	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^b	8 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) for patients who are HIV-uninfected and whose HCV RNA level is <6 million IU/mL	8 weeks	I, B
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

APRI	1.51
FIB-4	1.54
Fibrosure	F2

^a Includes genotype 1a resistance-associated substitutions (RASs) at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance. If 1 or more RASs are present, another recommended regimen should be used.

^b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 1a Patients With Compensated Cirrhosis^a •

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs ^b for elbasvir	12 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^c	8 weeks	I, B

^a For decompensated cirrhosis, please refer to the appropriate section.

^b Includes genotype 1a RASs at amino acid position 28, 30, 31, or 93 known to confer antiviral resistance. If 1 or more RASs are present, another recommended regimen should be used.

^c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. For patients with HIV/HCV coinfection, a treatment duration of 12 weeks is recommended.

Drug-Drug Interactions

	Ethinyl Estradiol (for example)
Route of Hormone Metabolism	3A4 (61%), 2C9 (23%), minor (<20% total): 1A2, 2C19, 3A5
EBR/GZR	\leftrightarrow
LDV/SOF	个 20%
SOF/VEL	\leftrightarrow
GP	个 28%-40%, ALT elevations observed
SOF/VEL/VOX	\leftrightarrow



Reference package inserts

Recommendations

- HCV GT1a, tx naïve, non-cirrhotic
 - Epclusa (SOF/VEL) x 12 weeks (also appropriate regimen for advanced fibrosis)
 - GLE/PIB & LDV/SOF: more pronounced LFT elevations with EE
 - EBV/GZR- need resistance testing
- Needs vaccination (HAV/HBV)





Case 218 – Dr. Adebajo

Baseline Demographics						
Age: 64	Race: Black	Gender: Female		Primary Insurance: Medicaid		
PMH/Comorbid	PMH/Comorbidities/Substance Use: None					
Pertinent Clinical Findings: None						
Weight (kg):	Not provided	Serum Albumin: Not provided ALT: 145				
Hgb:	14.9	Total bilirubin:	0.4	AST:	92	
PLT:	112	INR:	1.1	SCr/CrCl:	0.84/	



Case 218 – Dr. Adebajo

	HCV Evaluation					
Ultrasound: Pending	CT: Not done				MRI: Not done	
Signs of Cirrhosis:	None					
Staging Modality:	Results:	Interpretation:			APRI:	2.05
Fibroscan/Transient Elastography:	Pending				FIB-4:	4.37
Fibrosure:	0.73	-	F3-F4, severe necroinflammatory activity (0.87)			
Treatment Naïve?:	Yes	If no, previous treatment: HIV A		HIV Anti	body:	Negative
HCV Genotype:	1a	HCV RNA:	18,800,000	HAV Total Ab:		Negative
HBV sAb:	Positive	HBV sAg:	Negative	HBV Total cAb:		Non-reactive
Requested Regimen:	Epclusa x 12, Mavyret x 8 weeks					



Case 218 – Dr. Adebajo

Medication List:

- Amlodipine 2.5 mg daily
- Flonase as needed

Clinical considerations:

- GT1a, tx naïve, with compensated cirrhosis
- Platelets 112
- HBV sAb positive immune
- Received 1st dose of HepA vaccine (Havrix® or Vaqta®) – needs 2nd dose 6 months after first dose





Additional Pretreatment Assessment: Child-Turcotte-Pugh

Child-Turcotte-Pugh Classification for Severity of Cirrhosis

Points Clinical and Lab Criteria 2 3 1 Grade 1 or 2 Grade 3 or 4 Encephalopathy None Diuretic Diuretic None Ascites Responsive Refractory >3 Bilirubin (mg/dL) <2 2 - 3Albumin (g/dL) >3.5 2.8-3.5 <2.8 Prothrombin Time Seconds Prolonged 4 - 6>6 <4 or INR <1.7 1.7 - 2.3>2.3

Albumin not provided

Class A = 5-6 points Class B = 7-9 points Class C = 10-15 points

Cirrhosis with CTP Class B and C is considered decompensated

Pugh RN et al. Br J Surg. 1973;60:646-9.





HBV Evaluation

 Ensure adequate treatment of HBV as necessary prior to initiating HCV therapy

Marker	Interpretati on	Acute Infection	Window Period	Chronic Infection	Remote Infection	Immuni- zation	Inactive Chronic Carrier
HBcAb	Exposure	+	+	+	+	—	+
HBsAg	Infection	+	—	+		—	
HBsAb	Immunity	_	_		+	+	_

AASLD/IDSA HCV Guidelines. 2019.



Recommendations

Recommended regimens listed by evidence level and alphabetically for:

Treatment-Naive Genotype 1a Patients With Compensated Cirrhosis^a •

RECOMMENDED	DURATION	RATING
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASs ^b for elbasvir	12 weeks	I, A
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg)	12 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) ^c	8 weeks	I, B

^a For decompensated cirrhosis, please refer to the appropriate section.

^b Includes genotype 1a RASs at amino acid position 28, 30, 31, or 93 known to confer antiviral resistance. If 1 or more RASs are present, another recommended regimen should be used.

^c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. For patients with HIV/HCV coinfection, a treatment duration of 12 weeks is recommended.

GT1a, tx naïve, with compensated cirrhosis

All of the above are valid options

Different payers have different requirements & agents of choice



Recommendations

• GT1a, treatment naïve, compensated cirrhotic

- Epclusa[®] (SOF/VEL) x 12 weeks
- Mayvret[®] (GLE/PIB) x 8 weeks
- Harvoni[®] (LDV/SOF) x 12 weeks
- Zepatier[®] (EBV/GZR)- need resistance testing since GT1a
- HAV vaccination series in process

